Blog
RSS FeedPosted by Michael Wonder on 17 May 2021
Optimising managed access: lessons from the Cancer Drugs Fund
14 May 2021 - The desire, opportunity, and willingness to increase access to potentially life saving cancer treatments has mounted in ...
Posted by Michael Wonder on 04 May 2021
NICE announces more people eligible for nusinersen sodium following review of Managed Access Agreement
4 May 2021 - NICE has today announced that more people with the rare genetic disorder spinal muscular atrophy are to ...
Posted by Michael Wonder on 07 Apr 2021
Thousands to benefit from five minute breast cancer treatment
6 April 2021 - NHS England is rolling out an injection that dramatically cuts the amount of time breast cancer ...
Posted by Michael Wonder on 30 Mar 2021
Phenylketonuria sufferer has new hope for wonder drug after Government responds to plea
30 March 2021 - A teenager desperate to get a life-changing drug has been thrown a glimmer of hope by ministers. ...
Posted by Michael Wonder on 19 Mar 2021
Ovarian cancer patients to have NICE approved drug combination option on Cancer Drugs Fund
19 March 2021 - A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary ...
Posted by Michael Wonder on 14 Mar 2021
Doctors unlawfully denied drug to girl with spinal muscular atrophy, appeal court rules
5 March 2021 - Decisions made by two consultants to deny a 10 year old girl with type 3 spinal ...
Posted by Michael Wonder on 07 Sep 2020
AstraZeneca vaccine ‘most likely’ to roll out in the U.K. early next year
7 September 2020 - Rise in U.K. COVID cases is predominantly among younger people, health secretary says. ...
Posted by Michael Wonder on 02 Sep 2020
Novo launches type 2 diabetes pill in UK after NICE waives review
1 September 2020 - Novo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost ...
Posted by Michael Wonder on 22 Aug 2020
NHS cannabis guidelines challenged in court
18 August 2020 - The parents of a three-year-old boy with severe epilepsy are going to court to mount the ...
Posted by Michael Wonder on 13 Jul 2020
Are high‐cost drug funding mechanisms fit for purpose? A retrospective study of individual funding requests in an NHS tertiary hospital
13 July 2020 - This paper reports on a retrospective study of individual funding request submissions from a large tertiary hospital ...
Posted by Michael Wonder on 05 Jul 2020
Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal
5 July 2020 - Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for ...
Posted by Michael Wonder on 02 Jul 2020
Vertex announces expansion of reimbursement agreement with NHS England to include Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor)
30 June 2020 - Cystic fibrosis patients in England will be among the first in Europe to benefit from access to ...
Posted by Michael Wonder on 29 Jun 2020
Successful Eloctaq bid should widen access to the drug in the UK
29 June 2020 - The NHS and Sobi UK have come to an agreement that will give people living with ...
Posted by Michael Wonder on 23 Jun 2020
MHRA extends access to Santhera's DMD drug via the EAMS
23 June 2020 - The UK’s Medicines and Healthcare products Regulatory Agency has renewed for a further year the Early ...
Posted by Michael Wonder on 16 Mar 2020
HIV drug PrEP to be available across England
15 March 2020 - PrEP will be routinely available across England as part of the government’s aim to end HIV transmission ...